We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sponge on a String Detects Precursor to Esophageal Cancer

By LabMedica International staff writers
Posted on 28 Feb 2024
Print article
Image: The Cytosponge can be used to detect esophageal cancer earlier (Photo courtesy of Cancer Research UK)
Image: The Cytosponge can be used to detect esophageal cancer earlier (Photo courtesy of Cancer Research UK)

Esophageal cancer, which affects the food pipe, is a major cause of cancer deaths, ranking as the fourth highest in men and seventh in women. Its incidence is increasing, linked to risk factors like poor diet, smoking, alcohol use, and having a hiatus hernia. People with Barrett's esophagus are at a heightened risk for developing esophageal cancer. Endoscopy, a procedure involving a tiny camera inserted into the body, is used to diagnose various cancers, including those of the colon and stomach. Now, an innovative "sponge on a string" device coupled with a laboratory test can detect Barrett's esophagus, a precursor to esophageal cancer, offering a way to reduce the long waiting times for essential diagnostic tests.

The National Health Service (NHS, London, UK) conducted a trial of the "cytosponge," demonstrating its effectiveness in reducing the need for endoscopy. The cytosponge, a capsule about the size of a standard tablet, expands in the stomach once swallowed with water. It is then retrieved by pulling the attached string, and collecting cells for analysis to determine the presence of Barrett's esophagus. A simple antibody test then allows pathologists to easily spot signs of the precancerous condition. In a study involving 2,550 out of 8,500 patients tested with the cytosponge, it was found that 78% did not have Barrett's esophagus, allowing them to be monitored by their general practitioner instead of undergoing an endoscopy.

The trial also found that only 22% of those tested, who were at higher risk, required an endoscopic examination. This can not only speed up access to endoscopy for patients suspected of having higher-risk conditions but also significantly advance early cancer detection. The cytosponge is particularly appealing as it is quicker, less invasive, and more cost effective than traditional endoscopy. Experts believe this method could lead to earlier diagnosis of esophageal cancer, potentially reducing the need for late-stage treatments like chemotherapy and surgical removal of the esophagus.

Related Links:
NHS

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Multi-Purpose Centrifuge
GCC-MP
New
Anti-Thyroglobulin Reagent
Anti-TG Reagent Kit

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.